当前位置 >> 基金会介绍 >> 理事长
理事长

陈赛娟

陈赛娟,主任医师,教授,博士研究生导师,中国工程院院士,发展中国家科学院院士,法国医学科学院外籍院士,英国皇家内科学院院士,法国艾克斯-马赛大学名誉博士,第七、八届中国科学技术协会副主席,上海市科学技术协会主席,中华医学会副会长,上海医学会副会长,Frontiers of Medicine 主编 ,上海血液学研究所名誉所长,医学基因组学国家重点实验室主任,国家转化医学研究中心(上海)主任。十届、十一届全国人大代表 ,十二届、十三届全国政协委员。

陈赛娟教授近二十余年来主要从事血液恶性疾病发病机制和新型靶向治疗研究,率先发现急性单核细胞白血病DNA甲基转移酶基因突变是该类白血病的始动因素;发现RNA解旋酶DDX3X基因突变是天然杀伤/T细胞淋巴瘤诊断和预后判断的独特分子标志;系统阐明慢粒白血病和M2b白血病的多步骤发病原理;通过对急性T和B淋巴细胞白血病(ALL)的基因组全景式研究,构制了T和B急淋的基因突变和异常表达谱以及系列新的融合基因等药物作用的靶点;应用系统生物学研究思路,开展了急性髓系白血病(AML)的代谢组学研究;揭示了急性早幼粒细胞白血病(APL)砷剂作用的直接靶点,阐明砷剂“以毒攻毒”的分子机制,奠定了APL协同靶向治疗的分子基础。她注意基础与临床医学的结合,领导了APL的靶向治疗方案的设计与实施,使APL 实现了从高死亡率向高治愈率的转变。同时,她将这一成功思路进一步拓展至其他类型的白血病。陈赛娟团队阐明了传统中药冬凌草甲素对AML-M2b型白血病治疗的分子机制。最近她领导和组织的复发/难治多发性骨髓瘤患者用 LCAR-B38M的CAR-T探索性临床研究取得显著成效。她的研究对我国血液学科发展具重要的推动作用,产生了较大的国际影响。

陈赛娟教授团队在国际知名学术期刊发表论文500多篇,被引证数达30000余次。陈赛娟教授以第一完成人获得了包括国家自然科学二等奖(2次)、上海市自然科学奖特等奖在内的10余项重要科技奖项。

Prof. Sai-Juan Chen is a member of Chinese Academy of Engineering and the Academy of Sciences for the Developing World (TWAS), Foreign Associate of National Academy of Medicine of France, fellow of the Royal College of Physicians of UK. She holds the positions of Vice President of Chinese Medical Association, President of Shanghai Association of Science and Technology, Director of National Center for Translational Medicine·Shanghai, Director of State Key Laboratory of Medical Genomics, and Honorary Director of Shanghai Institute of Hematology.

Prof. Chen is engaged in the study of pathogenesis and treatment of leukemia. She initiated Leukemia Genomic Anatomy Project and has obtained a series of novel molecular biomarkers and targets for disease classification, prognosis and targeted therapy. Through screening and validation in large series of acute myeloid leukemia (AML) patients in Chinese population, she also established new diagnostic and prognostic stratification system of AML. These findings have further enriched and shed new light on pathogenesis of leukemia. Based on her understanding of the pathogenesis of leukemia, she innovated the synergistic targeted therapy of leukemia which has turned acute promyelocytic leukemia (APL) from a fatal malignancy to a curable disease, and has been extended to other types of leukemia.

Prof. Chen’s group has published over 500 publications in high level peer reviewed international journals including Science, Nature Genetics, Development Cell, JCI, Nature Commun., Blood and PNAS, with over 30000 citations. Her outstanding work has been recognized by several national awards in science, including Second Prize of National Natural Science Award by State Council of China.


版权所有:2014年 上海广慈转化医学发展研究基金会 技术支持:上海屹超
地址:上海广慈转化医学发展研究基金会 电话:021-181818 邮箱:161818616@163.com